Physician profile
Deep V Patel
NPI 1154593168
$59,590.06
in general payments reported to CMS, 2019-2025
19 companies · $4,645 in 2025
The $4,645 reported for 2025 was more than what 93% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $16K · 2020: $2,133 · 2021: $3,724 · 2022: $13K · 2023: $5,705 · 2024: $14K · 2025: $4,645.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $21K · Consulting Fee: $1,488 · Food and Beverage: $1,338 · Travel and Lodging: $577 · Education: $63.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $20,570.00 |
| Consulting Fee | $1,487.50 |
| Food and Beverage | $1,338.16 |
| Travel and Lodging | $576.54 |
| Education | $63.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $58,521.63 | 2019-2025 | Veltassa, Korsuva |
| Astrazeneca Pharmaceuticals LP | $167.14 | 2019-2025 | Lokelma, Farxiga |
| Medtronic, INC. | $139.88 | 2023-2024 | Ellipsys Vascular Access System, Venaseal |
| Otsuka America Pharmaceutical, INC. | $115.58 | 2024-2025 | Jynarque |
| Glaxosmithkline, LLC. | $113.69 | 2020-2021 | |
| Mallinckrodt Hospital Products INC. | $109.37 | 2023 | Terlivaz |
| Bayer Healthcare Pharmaceuticals INC. | $100.57 | 2023-2024 | |
| Travere Therapeutics, INC. | $62.20 | 2024-2025 | Filspari |
| Novartis Pharmaceuticals Corporation | $33.61 | 2025 | |
| Scpharmaceuticals INC. | $30.33 | 2025 | |
| Horizon Therapeutics Plc | $26.73 | 2023 | Krystexxa |
| Cormedix INC. | $26.25 | 2025 | Defencath |
| Janssen Biotech, INC. | $26.09 | 2024 | Tremfya |
| Amgen INC. | $25.42 | 2019 | |
| Akebia Therapeutics INC | $21.43 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Welch Allyn | $20.50 | 2021 | |
| Fresenius USA Marketing, INC. | $18.50 | 2024 | Velphoro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.54 | 2025 | Jardiance |
| Calliditas Therapeutics US INC. | $13.60 | 2023 | Tarpeyo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deep Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.